The data showed that human recombinant Trx-1 significantly inhibited ox-LDL-induced ROS production and apoptosis, suggesting that human recombinant Trx-1 may function as a novel therapeutic target in the prevention or treatment of atherosclerosis [154]. The gene discussed is TXN; the disease is atherosclerosis.